A therapeutic option in infants with functional constipation

2005, Number 2

Rev Gastroenterol Mex 2005; 70 (2)

Heller RS

Language: Spanish
References: 7
Page: 225
PDF size: 51.68 Kb.

Text Extraction

No Abstract

REFERENCES

Voskuijl W, de Lorijn F, Verwijs W, Hogeman P, et al. PEG 3350 (Transipeg) versus lactulose in the treatment of childhood functional constipation: a double blind, randomized, controlled, multicentre trial. Gut 2004; 53: 1560-4.
Pashankar D, Uc A, Bishop W. Polyethylene glycol 3350 without electrolytes: a new safe, effective, and palatable bowel preparation for colonoscopy in children. J Pediatr 2004; 144: 358-62.
Pashankar DS, Bishop WP. Efficacy and optimal dose of daily polyethylene glycol 3350 for treatment of constipation and encopresis in children. Pediatr 2001; 139: 428-32.
Youssef NN, Peters JM, Henderson W, et al. Dose response of PEG 3350 for the treatment of childhood fecal impaction. J Pediatr 2002; 141: 410-4.
Pashankar DS, Loening-Baucke V, Bishop WP. Long- term efficacy of polyethylene glycol 3350 for the treatment of chronic constipation in children. Arch Pediatr Adolesc Med 2003; 157: 661-4.
Erickson BA, Austin JC, Cooper CS, Boyt MA. Polyethylene glycol 3350 for constipation in children with dysfunctional elimination. J Urol 2003; 170: 1518-20.
Michael S, Gendy E, Preud´Homme D, Mezoff A. Polyethylene glycol for constipation in children younger than eighteen months old. J Pediatr Gastroenterol Nutr 2004; 39: 197-9.